Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-25
2010-11-09
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S327000, C514S328000, C546S242000
Reexamination Certificate
active
07829579
ABSTRACT:
Provided is a method of increasing the stability of wild-type β-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of β-glucocerebrosidase in the central nervous system would be beneficial. This method includes administering an effective amount of a pharmacologic chaperone for β-glucocerebrosidase, with the proviso that the individual does not have a mutation in the gene encoding β-glucocerebrosidase. Further provided are β-glucocerebrosidase inhibitors which have been identified as specific pharmacologic chaperones and which have been shown to increase activity of β-glucocerebrosidase in vivo in the central nervous system.
REFERENCES:
patent: 6583158 (2003-06-01), Fan et al.
patent: 6916829 (2005-07-01), Fan et al.
patent: 2002/0035072 (2002-03-01), Fan et al.
patent: 2003/0119874 (2003-06-01), Fan et al.
patent: 2007/0281975 (2007-12-01), Mugrage et al.
patent: 2 354 946 (2001-04-01), None
patent: 2004 069190 (2004-08-01), None
patent: 2005046611 (2005-05-01), None
patent: 2006 133446 (2006-12-01), None
patent: 2008 144773 (2008-11-01), None
Selkoe, D.J. Nature Cell Biology, Nov. 2004, vol. 6, No. 11, pp. 1054-1061.
Webster's Ninth New Collegiate Dictionary, 2002, Definition of Prevention, p. 1.
Schlossmacher et al. New England Journal of Medicine, Feb. 2005, vol. 352, Issue 7, pp. 729-731.
Agid et al. Movement Disorders, 1999, vol. 14, No. 6, pp. 911-913.
Aharon-Peretz et al., “Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews.” The New England Journal of Medicine, 351: 1972-1977 (2004).
Butters et al., “Therapeutic Applications of Imino Sugars in Lysosomal Storage Disorders.” Current Topics in Medicinal Chemistry, 3: 561-74 (2003).
Clark et al., “Pilot Association Study of the β-Glucocerebrosidase N370S Allele and Parkinson's Disease in Subjects of Jewish Ethnicity.” Movement Disorders, 20(1): 100-103 (2005).
Farrer et al., “Glucosidase-beta variations and Lewy body disorders.” Parkinsonism and Related Disorders xxx: 1-3 (2008).
Goker-Alpan et al., “Parkinsonism among Gaucher disease carriers.” J. Med Genet, 41: 937-940 (2004).
Hruska et al., “Gaucher Disease and the Synucleinopathies.” J. of Biomed and Biotech, 2006: 1-6 (2006).
Lwin et al., “Glucocerebrosidase mutations in subjects with parkinsonism.” Molecular Genetics and Metabolsim 81: 70-73 (2004).
Office Action dated May 15, 2008 for U.S. Appl. No. 11/449,528.
Office Action dated Nov. 10, 2008 for U.S. Appl. No. 11/449,528.
Office Action dated Mar. 25, 2009 for U.S. Appl. No. 11/449,528.
Office Action-Advisory Action dated May 19, 2009 for U.S. Appl. No. 11/449,528.
Office Action dated Aug. 6, 2009 for U.S. Appl. No. 11/449,528.
Office Action-Interview Summary dated Oct. 21, 2009 for U.S. Appl. No. 11/449,528.
Office Action-Final dated Mar. 24, 2010 for U.S. Appl. No. 11/449,528.
Ruvinov et al., “Monovalent Cations Partially Repair a Conformational Defect in a Mutant Tryptophan Synthase α2β2 Complex (β-E109A)*.” The Journal of Biological Chemistry 270(29): 17333-17338 (1995).
Sidransky, E., “Gaucher disease: complexity in a “simple” disorder.” Molecular Genetics and Metabolism 83: 6-15 (2004).
Sidransky, E., “Gaucher disease and parkinsonism.” Molecular Genetics and Metabolism 84: 302-304 (2005).
Sawkar et al., “Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease.” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, US, vol. 99, No. 24, Nov. 26, 2002, pp. 15428-15433.
Tayebi et al., “Gaucher Disease with Parkinsonian Manifestations: Does Glucocerebrosidase Deficiency Contribute to Vulnerability to Parkonsonism?” Mol. Genet. Metab. 79(2): 104-9 (2003).
The Michael J. Fox Foundation for Parkinson's Research, Letter to Brandon Wutsman, PhD and Sean Clark, PhD. Dec. 8, 2006.
The Michael J. Fox Foundation for Parkinson's Research. “Principal Investigator on Application: Brandon Wustman.” Target Validation 2006 RFA.
LJ Ozelius et al., “LRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews.” New England Journal of Medicine, No. 4, 354 424-425 (2006).
Wong et al., “Neuropathology Provides Clues to the Pathophysiology of Gaucher Disease.” Molecular Genetics and Metabolism 82: 192-207 (2004).
Emyr Lloyd-Evans et al., “Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms”, The Journal of Biological Chemistry, vol. 278, No. 26, issue Jun. 27, pp. 23594-23599, 2003.
Bernard Brugg et al., “Ceramide induces apoptosis in cultured mesencephalic neurons”, Journal of Neurochemistry, vol. 66, pp. 733-739, 1996.
Eduard Orvisky et al., “Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype”, Molecular Genetics and Metabolism, vol. 76, issue 4, pp. 262-270, 2002.
Eduard Korkotian et al., “Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons”, The Journal of Biological Chemistry, vol. 274, No. 31, issue Jul. 30, pp. 21673-21678, 1999.
Michael J. Eblan et al., “Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism”, Neuroscience Letters, Elsevier, NSL-23190, 3 pages, 2006.
Doug A. Brooks, “Getting into the fold”, Nature Chemical Biology, vol. 3, No. 2, 2007.
Amicus Therapeutics, Inc.
Hoffmann & Baron , LLP
Jean-Louis Samira
Padmanabhan Sreeni
LandOfFree
Method for the treatment of neurological disorders by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of neurological disorders by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of neurological disorders by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170244